Haploidentical Hematopoietic Stem Cell Transplantation Followed by ‘Post-Cyclophosphamide’: The Future of Allogeneic Stem Cell Transplant

Authors

Samuel Cytryn¹, Maher Abdul-Hay^{1, 2, *,}

¹New York University School of Medicine and Department of Medicine, New York, NY, USA

²Department of Hematology and Medical Oncology, New York University Perlmutter Cancer Center, New York, NY, USA

^*Corresponding author. Postal address: Assistant Professor of Medicine, NYU School of Medicine, 240 East 38th street, 19Floor, New York, NY 10016. Tel.: 646-501-4818, Fax: 646-754-9844. Email: maher.abdulhay@nyulangone.org

DOI

10.2991/chi.d.200405.001How to use a DOI?

Keywords

Haploidentical; Allogeneic; Posttransplant cyclophosphamide

Abstract

Allogeneic hematopoietic cell transplant (Allo-HCT) is a potentially curative therapy for many malignant and nonmalignant hematological diseases. However, a suitable human leukocyte antigens (HLAs)-matched donor may not be available when the patient is in urgent need of a stem cell transplant. This challenge has been ameliorated to a large extent by the introduction of haploidentical donors. This type of donor shares one HLA haplotype with the recipient. Therefore, a patient's full sibling has a 50% chance of being haploidentical and a patient's biologic parents and children will all be haploidentical, thus providing an immediately accessible, motivated donor for almost every recipient. Haploidentical transplants previously incurred prohibitively poor outcomes, preventing their widespread use. However, several recent advances have dramatically improved the results, making them a more viable donor source. In this review, we discuss different types of donors used for Allo-HCT with a particular focus on the use of haploidentical donors and their future potential.

Copyright

© 2020 International Academy for Clinical Hematology. Publishing services by Atlantis Press International B.V.

Open Access

This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).

Download article (PDF)
View full text (HTML)

TY  - JOUR
AU  - Samuel Cytryn
AU  - Maher Abdul-Hay
PY  - 2020
DA  - 2020/04/19
TI  - Haploidentical Hematopoietic Stem Cell Transplantation Followed by ‘Post-Cyclophosphamide’: The Future of Allogeneic Stem Cell Transplant
JO  - Clinical Hematology International
SP  - 49
EP  - 58
VL  - 2
IS  - 2
SN  - 2590-0048
UR  - https://doi.org/10.2991/chi.d.200405.001
DO  - 10.2991/chi.d.200405.001
ID  - Cytryn2020
ER  -